It is especially useful in assessing the risk of recurrence for estrogen receptor (ER)-positive HER2-negative breast cancers, where it may be considered a surrogate of the molecular assays for distinguishing Luminal A-like from Luminal B-like tumors [2]. This evidence concerns the gene ESR1 and breast cancer.